Previous 10 | Next 10 |
EDINBURGH, United Kingdom, May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference. Event: Jeff...
Gainers: Surface Oncology (NASDAQ: SURF ) +82% . More news on: Surface Oncology, Inc., Nabors Industries Ltd., LMP Automotive Holdings, Inc., Stocks on the move, , Read more ...
NuCana (NASDAQ: NCNA ): Q1 GAAP EPS of -£0.12 beats by £0.07 . More news on: NuCana plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021 EDINBURGH, United K...
EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its ...
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Ca...
EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has b...
EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies. In order to help to protect the...
Gainers: DXC +34.3% . ALT +20.7% . CNDT +14.6% . CLDR +12.1% . NCNA +10.2% . More news on: DXC Technology Company, Altimmune, Inc., Conduent Incorporated, Stocks on the move, , News on ETFs Read more ...
Preliminary data from a Phase 2 clinical trial evaluating NuCana's (NASDAQ: NCNA ) Acelarin (NUC-1031) in heavily pretreated patients with platinum-resistant ovarian cancer showed a treatment effect. More news on: NuCana plc, Healthcare stocks news, Stocks on the move, Read more ....
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 37.1% to $0.1629 on volume of 102,747,129 shares WiSA Technologies Inc. (WISA) rose 69.1% to $2.96 on volume of 24,734,833 shares Peraso Inc. (PRSO) rose 37.0% to $1.7393 on volume of 23,546,162 shares ...
EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the Company’s previously disclosed plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinar...